FBXO7 and cancer: Beyond these co-opted E3 ligases, we identified 363 (33.8%) potentially novel E3 ligases highly expressed in over 30 cancer types, such as HUWE1 and FBXO7, indicating the high potential of these E3 ligases for pan-cancer usage (Fig. 3a).